Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist
Abstract We report the discovery of strong HNF4α agonists and their use to uncover a previously unknown pathway by which HNF4α controls the level of fat storage in the liver. This involves the induction of lipophagy by dihydroceramides, the synthesis and secretion of which is controlled by genes ind...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-021-03862-x |
id |
doaj-e294ac4cd62f4a9f87cb27d51d5aadbf |
---|---|
record_format |
Article |
spelling |
doaj-e294ac4cd62f4a9f87cb27d51d5aadbf2021-06-13T11:05:55ZengNature Publishing GroupCell Death and Disease2041-48892021-06-0112611810.1038/s41419-021-03862-xLiver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonistSeung-Hee Lee0Vimal Veeriah1Fred Levine2SBP Medical Discovery InstituteSBP Medical Discovery InstituteSBP Medical Discovery InstituteAbstract We report the discovery of strong HNF4α agonists and their use to uncover a previously unknown pathway by which HNF4α controls the level of fat storage in the liver. This involves the induction of lipophagy by dihydroceramides, the synthesis and secretion of which is controlled by genes induced by HNF4α. The HNF4α activators are N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT), which are structurally related to the known drugs alverine and benfluorex, which we previously showed to be weak HNF4α activators. In vitro, NCT and NFT induced fat clearance from palmitate-loaded cells. In DIO mice, NCT led to recovery of hepatic HNF4α expression and reduction of steatosis. Mechanistically, increased dihydroceramide production and action downstream of HNF4α occurred through increased expression of HNF4α downstream genes, including SPNS2 and CYP26A1. NCT was completely nontoxic at the highest dose administered and so is a strong candidate for an NAFLD therapeutic.https://doi.org/10.1038/s41419-021-03862-x |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Seung-Hee Lee Vimal Veeriah Fred Levine |
spellingShingle |
Seung-Hee Lee Vimal Veeriah Fred Levine Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist Cell Death and Disease |
author_facet |
Seung-Hee Lee Vimal Veeriah Fred Levine |
author_sort |
Seung-Hee Lee |
title |
Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist |
title_short |
Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist |
title_full |
Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist |
title_fullStr |
Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist |
title_full_unstemmed |
Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist |
title_sort |
liver fat storage is controlled by hnf4α through induction of lipophagy and is reversed by a potent hnf4α agonist |
publisher |
Nature Publishing Group |
series |
Cell Death and Disease |
issn |
2041-4889 |
publishDate |
2021-06-01 |
description |
Abstract We report the discovery of strong HNF4α agonists and their use to uncover a previously unknown pathway by which HNF4α controls the level of fat storage in the liver. This involves the induction of lipophagy by dihydroceramides, the synthesis and secretion of which is controlled by genes induced by HNF4α. The HNF4α activators are N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT), which are structurally related to the known drugs alverine and benfluorex, which we previously showed to be weak HNF4α activators. In vitro, NCT and NFT induced fat clearance from palmitate-loaded cells. In DIO mice, NCT led to recovery of hepatic HNF4α expression and reduction of steatosis. Mechanistically, increased dihydroceramide production and action downstream of HNF4α occurred through increased expression of HNF4α downstream genes, including SPNS2 and CYP26A1. NCT was completely nontoxic at the highest dose administered and so is a strong candidate for an NAFLD therapeutic. |
url |
https://doi.org/10.1038/s41419-021-03862-x |
work_keys_str_mv |
AT seungheelee liverfatstorageiscontrolledbyhnf4athroughinductionoflipophagyandisreversedbyapotenthnf4aagonist AT vimalveeriah liverfatstorageiscontrolledbyhnf4athroughinductionoflipophagyandisreversedbyapotenthnf4aagonist AT fredlevine liverfatstorageiscontrolledbyhnf4athroughinductionoflipophagyandisreversedbyapotenthnf4aagonist |
_version_ |
1721380204958449664 |